Given the evidence for overexpression of PRMT5 as a driver in human and lymphoma associated with malignant activity in canine lymphoma, this model represents an ideal large animal platform for continued investigation and potential veterinary-clinical trials evaluating the activity and efficacy of PRMT5 inhibitors for NHL. This evidence concerns the gene PRMT5 and non-Hodgkin lymphoma.